Tag Archives: Albireo Pharma Inc

H.C. Wainwright Sticks to Their Buy Rating for Albireo Pharma Inc (ALBO)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma Inc (ALBO – Research Report) on August 9 and set a price target of $62. The company’s shares closed on Friday at $22.86. According to TipRanks.com, Arce is

H.C. Wainwright Keeps Their Buy Rating on Albireo Pharma Inc (ALBO)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma Inc (ALBO – Research Report) today and set a price target of $62. The company’s shares closed yesterday at $31.88. According to TipRanks.com, Arce is a 4-star analyst

Analysts Offer Insights on Healthcare Companies: Albireo Pharma Inc (NASDAQ: ALBO), Adverum Biotechnologies (NASDAQ: ADVM) and Incyte Corp (NASDAQ: INCY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma Inc (ALBO – Research Report), Adverum Biotechnologies (ADVM – Research Report) and Incyte Corp (INCY – Research Report) with bullish

Albireo Pharma Inc (ALBO) Received its Third Buy in a Row

After H.C. Wainwright and Needham gave Albireo Pharma Inc (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma Inc today and set a

Albireo Pharma Inc (ALBO) Initiated with a Buy at H.C. Wainwright

Albireo Pharma Inc (ALBO – Research Report) received a Buy rating and a $62 price target from H.C. Wainwright analyst Ed Arce today. The company’s shares closed yesterday at $26.80. According to TipRanks.com, Arce is a 4-star analyst with an

Albireo Pharma Inc (ALBO) Gets a Buy Rating from Wedbush

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Albireo Pharma Inc (ALBO – Research Report), with a price target of $69. The company’s shares opened today at $23.30. According to TipRanks.com, Moussatos ‘ ranking